Skip to main content
Johnson & Johnson10-Q: Restructuring

JNJ commits over $2B to multi-year restructuring of Innovative Medicine, Surgery, and Orthopaedics units.

What happened

JNJ is executing three major restructuring programs to streamline operations, exit non-strategic markets and product lines, and optimize its manufacturing footprint. This massive organizational shift creates significant needs for consulting, change management, process automation, and new technology solutions to support the redesigned business units.

Source

SEC EDGARJul 23, 2026

Quarterly report (Form 10-Q)

Johnson & Johnson 10-Q

Filing excerpt

In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million...

sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htmRead the full source

Other signals in this filing (9)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Restructuring

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/28
Filed
Jul 23, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$2.4B (Total estimated costs for three major restructuring programs across Innovative Medicine ($700M), Surgery ($650M), and Orthopaedics ($1000M) segments, using...)

Details

CIK
200406
Accession number
0000200406-26-000153
Timeframe
Current year
Filing year
2026
Fiscal year
0
Why it matters
Change management needs
Signal category
Workforce

Topics and mentions

Competitors

  • generic and biosimilar manufacturers

Extraction

Confidence
High
Relevance
90%
Sentiment
Neutral
Detected
Jul 28, 2026
signal_type
sec-10q
signal_subtype
restructuring

Use this data

Get every 10-Q signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/49a49339-765c-47d6-bced-15f2cb9b5eee returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "49a49339-765c-47d6-bced-15f2cb9b5eee",
  "signal_type": "sec-10q",
  "signal_subtype": "restructuring",
  "detected_at": "2026-07-28T07:07:29.675+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "detail": "JNJ is executing three major restructuring programs to streamline operations, exit non-strategic markets and product lines, and optimize its manufacturing footprint. This massive organizational shift creates significant needs for consulting, change management, process automation, and new technology solutions to support the redesigned business units.",
    "metrics": {
      "timeframe": "current_year",
      "dollar_context": "Total estimated costs for three major restructuring programs across Innovative Medicine ($700M), Surgery ($650M), and Orthopaedics ($1000M) segments, using mid-points of ranges.",
      "dollar_millions": 2350
    },
    "summary": "JNJ commits over $2B to multi-year restructuring of Innovative Medicine, Surgery, and Orthopaedics units.",
    "excerpts": "In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million...",
    "relevance": 0.9,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm",
    "filing_date": "2026-07-23",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/28",
    "sales_relevance": "Change management needs",
    "signal_category": "workforce",
    "competitors_mentioned": [
      "generic and biosimilar manufacturers"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.